University of Leicester
Browse
191122 MJD comments 5039 Buse Consensus Report Update proofs.pdf (1.34 MB)

2019 update to: Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)

Download (1.34 MB)
journal contribution
posted on 2020-02-21, 16:07 authored by JB Buse, DJ Wexler, A Tsapas, P Rossing, G Mingrone, C Mathieu, DA D’Alessio, MJ Davies
The American Diabetes Association and the European Association for the Study of Diabetes have briefly updated their 2018 recommendations on management of hyperglycaemia, based on important research findings from large cardiovascular outcomes trials published in 2019. Important changes include: (1) the decision to treat high-risk individuals with a glucagon-like-peptide 1 (GLP-1) receptor agonist or sodium–glucose cotransporter 2 (SGLT2) inhibitor to reduce major adverse cardiovascular events (MACE), hospitalisation for heart failure (hHF), cardiovascular death or chronic kidney disease (CKD) progression should be considered independently of baseline HbA1c or individualised HbA1c target; (2) GLP-1 receptor agonists can also be considered in patients with type 2 diabetes without established cardiovascular disease (CVD) but with the presence of specific indicators of high risk; and (3) SGLT2 inhibitors are recommended in patients with type 2 diabetes and heart failure, particularly those with heart failure with reduced ejection fraction, to reduce hHF, MACE and CVD death, as well as in patients with type 2 diabetes with CKD (eGFR 30 to ≤60 ml min−1 [1.73 m]−2 or urinary albumin-to-creatinine ratio >30 mg/g, particularly >300 mg/g) to prevent the progression of CKD, hHF, MACE and cardiovascular death.

History

Citation

Diabetologia 63, 221–228 (2020). https://doi.org/10.1007/s00125-019-05039-w

Author affiliation

Diabetes Research Centre, University of Leicester

Version

  • AM (Accepted Manuscript)

Published in

Diabetologia

Volume

63

Pagination

221-228

Publisher

Springer Science and Business Media LLC

issn

0012-186X

eissn

1432-0428

Copyright date

2019

Notes

This article is being simultaneously published in Diabetologia (https://doi.org/10.1007/s00125-019-05039-w) and Diabetes Care (https://doi.org/10.2337/dci19-0066) by the European Association for the Study of Diabetes and the American Diabetes Association. Correction: Diabetologia https://doi.org/10.1007/s00125-020-05151-2 The incorrect figure legend was printed for Fig. 2. The correct legend should have read ‘Choosing glucose-lowering medication in those with indicators of high-risk or established athero-sclerotic cardiovascular disease (ASCVD), chronic kidney disease (CKD) or heart failure (HF)’, as per the figure heading.

Spatial coverage

Germany

Language

eng

Publisher version

https://link.springer.com/article/10.1007/s00125-019-05039-w

Usage metrics

    University of Leicester Publications

    Categories

    No categories selected

    Exports

    RefWorks
    BibTeX
    Ref. manager
    Endnote
    DataCite
    NLM
    DC